Literature DB >> 2836950

Chimeric alpha 2-,beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity.

B K Kobilka1, T S Kobilka, K Daniel, J W Regan, M G Caron, R J Lefkowitz.   

Abstract

The alpha 2 and beta 2 adrenergic receptors, both of which are activated by epinephrine, but which can be differentiated by selective drugs, have opposite effects (inhibitory and stimulatory) on the adenylyl cyclase system. The two receptors are homologous with each other, rhodopsin, and other receptors coupled to guanine nucleotide regulatory proteins and they contain seven hydrophobic domains, which may represent transmembrane spanning segments. The function of specific structural domains of these receptors was determined after construction and expression of a series of chimeric alpha 2-,beta 2-adrenergic receptor genes. The specificity for coupling to the stimulatory guanine nucleotide regulatory protein lies within a region extending from the amino terminus of the fifth hydrophobic domain to the carboxyl terminus of the sixth. Major determinants of alpha 2- and beta 2-adrenergic receptor agonist and antagonist ligand binding specificity are contained within the seventh membrane spanning domain. Chimeric receptors should prove useful for elucidating the structural basis of receptor function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836950     DOI: 10.1126/science.2836950

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  137 in total

1.  Topology studies with biosynthetic fragments identify interacting transmembrane regions of the human red-cell anion exchanger (band 3; AE1).

Authors:  J D Groves; M J Tanner
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

Review 2.  Structural features of heterotrimeric G-protein-coupled receptors and their modulatory proteins.

Authors:  H LeVine
Journal:  Mol Neurobiol       Date:  1999-04       Impact factor: 5.590

3.  Dominance of G(s) in doubly G(s)/G(i)-coupled chimaeric A(1)/A(2A) adenosine receptors in HEK-293 cells.

Authors:  A L Tucker; L G Jia; D Holeton; A J Taylor; J Linden
Journal:  Biochem J       Date:  2000-11-15       Impact factor: 3.857

4.  Effects of defolliculation on membrane current responses of Xenopus oocytes.

Authors:  R Miledi; R M Woodward
Journal:  J Physiol       Date:  1989-09       Impact factor: 5.182

5.  Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor.

Authors:  P Ghanouni; J J Steenhuis; D L Farrens; B K Kobilka
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

6.  Structural insight into the role of the human melanocortin 3 receptor cysteine residues on receptor function.

Authors:  Yingkui Yang; Min Chen; David McPherson; Vinod Mishra; Carroll M Harmon
Journal:  Peptides       Date:  2011-10-31       Impact factor: 3.750

7.  Molecular structural basis of ligand selectivity for 5-HT2 versus 5-HT1C cortical receptors.

Authors:  P A Pierce; J Y Kim; S J Peroutka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

8.  Antipeptide antibodies to the beta 2-adrenergic receptor confirm the extracellular orientation of the amino-terminus and the putative first extracellular loop.

Authors:  M A Théveniau; J R Raymond; G N Rougon
Journal:  J Membr Biol       Date:  1989-10       Impact factor: 1.843

9.  Characterization and functional expression in mammalian cells of genomic and cDNA clones encoding a Drosophila muscarinic acetylcholine receptor.

Authors:  R A Shapiro; B T Wakimoto; E M Subers; N M Nathanson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

10.  Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.

Authors:  U Gether; Y Yokota; X Emonds-Alt; J C Brelière; J A Lowe; R M Snider; S Nakanishi; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.